11 recruiting, 4 not yet recruiting, 1 active not recruiting, 1 available. 12 Phase 1, 6 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 7, Not yet recruiting 4, Active not recruiting 1 |
| Phase 2 | 6 | Not yet recruiting 3, Recruiting 3 |
| Not applicable | 1 | Recruiting 1 |
Follow Advanced Solid Tumor Cancer: new trials by email Literature Review of Advanced Solid Tumor Cancer trials Research Report on Advanced Solid Tumor Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors LM-364 for injection, Tislelizumab - Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | Not yet recruiting | LaNova Medicines Limited | 90 | 2026-10-19 | 2026-10-14 |
| A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors YF087 - Advanced Solid Tumor Cancer | Phase 1 | Not yet recruiting | InventisBio Co., Ltd | 70 | 2026-09-18 | 2026-09-09 |
| Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease Tislelizumab + Bevacizumab + Capecitabine - Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | Not yet recruiting | National University Hospital, Singapore | 154 | 2026-08-01 | 2026-07-10 |
| A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors ZE94-0605 - Advanced Solid Tumor Cancer, Metastatic Solid Tumor | Phase 1 | Recruiting | Eilean Therapeutics | 60 | 2026-06-25 | 2026-07-29 |
| The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer Written Exposure-Based Coping Intervention (EASE), Usual Care Control Condition - Advanced Solid Tumor Cancer, Stage IV Cancer (Solid Tumors Only) | Not applicable | Recruiting | University of Colorado, Boulder | 250 | 2026-05-04 | 2026-06-09 |
| Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors BNT3214 - Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 533 | 2026-03-30 | 2026-08-13 |
| A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors HC010, Paclitaxel, Oxaliplatin - Advanced Solid Tumor Cancer | Phase 1 | Recruiting | HC Biopharma Inc. | 331 | 2026-03-17 | 2026-03-17 |
| A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors Phase I dose escalation, Phase I: Dose Expansion, phase II - Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | Not yet recruiting | Suzhou Genhouse Bio Co., Ltd. | 152 | 2026-02-24 | 2026-03-03 |
| Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies SHR-A1811, Trastuzumab Rezetecan - Urachal Cancer, Advanced Solid Tumor Cancer | Phase 2 | Recruiting | Sheng Zhang | 90 | 2025-12-18 | 2025-12-30 |
| Phase II Study of LM-24C5 LM-24C5 - Advanced Solid Tumor Cancer | Phase 2 | Recruiting | LaNova Medicines Limited | 130 | 2025-12-15 | 2026-02-04 |
| A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer HC010, Paclitaxel (Chemotherapy), Pemetrexed - Advanced Solid Tumor Cancer | Phase 1 | Recruiting | HC Biopharma Inc. | 328 | 2025-10-27 | 2026-02-02 |
| The Added Value of Tissue or Liquid Biopsy NGS Profiling in Advanced Solid Tumor Treatment Decisions. Comprehensive NGS testing - Advanced Solid Tumor Cancer, Primary CNS Tumors | Recruiting | The Belgian Society of Medical Oncology | 550 | 2025-10-22 | 2026-07-20 | |
| Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors YK1101 cells - Advanced Solid Tumor Cancer | Phase 1 | Recruiting | Peking University | 10 | 2025-04-27 | 2025-08-24 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GH2616 in Subjects With Advanced Solid Tumor. GH2616 Tablets for oral administration at specified doses on scheduled days. - Advanced Solid Tumor Cancer | Phase 1 | Active not recruiting | Suzhou Genhouse Bio Co., Ltd. | 126 | 2025-03-27 | 2025-12-03 |
| X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma X-PACT - Advanced Solid Tumor Cancer | Phase 1 | Recruiting | Immunolight, LLC | 52 | 2021-12-08 | 2026-01-30 |
| Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor - Advanced Solid Tumor Cancer | Phase 1 | Recruiting | Calico Life Sciences LLC | 248 | 2021-03-09 | 2026-06-04 |
| Expanded Access to ABBV-CLS-484 DRUG: ABBV-CLS-484 - Advanced Solid Tumor Cancer | Available | Calico Life Sciences LLC | 2024-01-03 |
Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Central Nervous System Diseases (1) · Glioblastoma (1) · Head and Neck Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Paget Disease, Extramammary (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1) · Urachal cancer (1)
Neoplasms (4) · Neoplasms by Site (4) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (2) · Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Adnexal Diseases (1) · Astrocytoma (1) · Breast Diseases (1)
Capecitabine (2) · Paclitaxel (2) · osunprotafib (2) · tislelizumab (2) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Clinical Trials, Phase II as Topic (1) · Docetaxel (1) · Drug Therapy (1) · Etoposide (1) · Injections (1) · Oxaliplatin (1) · Pemetrexed (1) · Receptors, Vascular Endothelial Growth Factor (1)
Calico Life Sciences LLC (2) · HC Biopharma Inc. (2) · LaNova Medicines Limited (2) · Suzhou Genhouse Bio Co., Ltd. (2) · BioNTech SE (1) · Eilean Therapeutics (1) · Immunolight, LLC (1) · InventisBio Co., Ltd (1) · National University Hospital, Singapore (1) · Peking University (1) · Sheng Zhang (1) · The Belgian Society of Medical Oncology (1) · University of Colorado, Boulder (1)
China (9) · United States (3) · Australia (2) · South Korea (2) · Belgium (1) · France (1) · Israel (1) · Japan (1) · Singapore (1) · Spain (1) · Taiwan (1) · Uzbekistan (1)
Kevin Punie, Oncologist (1) · Philippe Aftimos, Oncologist (1) · Ruihua Xu, MD (1) · Soo Chin Lee (1) · William Eward, MD (1)
2023 (1), R01CA300028 (1)